Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.

The Cigna Group is set to report its Q2 2025 earnings on July 31, with analysts expecting a 6.3% profit jump year-over-year.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

WW International relists on Nasdaq, pivoting to menopause care with GLP-1 drugs and coaching. Click here to read an analysis ...

Merck MRK recently intensified its acquisition strategy, actively pursuing deals to enhance its development pipeline and ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

If you sized SANA small after the May post, the thesis is tracking; consider letting winners run while watching for pullbacks ...

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Share Market Highlights - Find here all the updates related to Sensex, Nifty, BSE, NSE, share prices and Indian stock markets for 14th July 2025 ...